抗白细胞介素类抗体治疗银屑病的临床研究进展

Clinical research progress of anti-interleukin antibody in the treatment of psoriasis

银屑病是一种多基因遗传的自身免疫性皮肤疾病,目前尚不能根治。IL-23/IL-17轴是银屑病发病机制中最重要的通路,针对这一通路开发出了一系列抗白细胞介素类生物制剂。其中包括作用于IL-17A的苏金单抗和艾克珠单抗;作用于IL-17受体的布罗达单抗;作用于IL-12/IL-23的P40亚基的ustekinumab;作用于IL-23的P19亚基的Guselkumab、Tildrakizumab及Risankizumab。该类抗体表现出良好疗效,给银屑病的治疗提供了新的选择。

Psoriasis is a multigene autoimmune skin disease without cure.The iL-23/iL-17 axis is the most important pathway in the pathogenesis of psoriasis,and a series of interleukin agents have been developed for this pathway,including secukinumab and ixekizumab in iL-17 a,the brodalumab monoclonal antibody acting on the iL-17 receptor,the ustekinumab acting on P40 subunit of iL-12/iL-23,and guselkumab,tildrakizumab and risankizumab acting on P19 subunit of iL-23.This group of antibodies shows good efficacy and provides a new choice for the treatment of psoriasis.